Class II · Moderate risk
All quinine Products
Lack of Processing Controls
FDA Drug Recalls
1,356 recalls, newest first
Class II · Moderate risk
All hydroxyzine Products
Lack of Processing Controls
Class II · Moderate risk
All budesonide Products
Lack of Processing Controls
Class II · Moderate risk
All cetirizine Products
Lack of Processing Controls
Class II · Moderate risk
All arginine Products
Lack of Processing Controls
Class II · Moderate risk
All T4-levothyroxine Products
Lack of Processing Controls
Class II · Moderate risk
All thymol Products
Lack of Processing Controls
Class II · Moderate risk
All PCCA Lipoderm Products
Lack of Processing Controls
Class II · Moderate risk
All tetracaine Products
Lack of Processing Controls
Class II · Moderate risk
All propylparaben Products
Lack of Processing Controls
Class II · Moderate risk
All methimazole Products
Lack of Processing Controls
Class II · Moderate risk
All fluocinonide Products
Lack of Processing Controls
Class II · Moderate risk
All Germall
Lack of Processing Controls
Class II · Moderate risk
All betamethasone diproprionate Products
Lack of Processing Controls
Class II · Moderate risk
All monobenzone Products
Lack of Processing Controls
Class II · Moderate risk
All carbomer Products
Lack of Processing Controls
Class II · Moderate risk
All progesterone Products
Lack of Processing Controls
Class II · Moderate risk
All Peterson Cream Products
Lack of Processing Controls
Class II · Moderate risk
All TRIE Products
Lack of Processing Controls
Class II · Moderate risk
All estriol Products
Lack of Processing Controls
Class II · Moderate risk
All testosterone Products
Lack of Processing Controls
Class II · Moderate risk
All 4-aminopyridine Products
Lack of Processing Controls
Class III · Low risk
Oxygen
CGMP Deviations: Cylinders filled using out of date gauges.
Class II · Moderate risk
Oxygen
cGMP Deviations; trailer may not have met GMP requirements prior to filling
Class III · Low risk
FUROSEMIDE Tablets USP
CGMP Deviations: The active pharmaceutical ingredient (API) intended for use in furosemide oral solution USP was inadvertently used to manufacture the recalled furosemide tablets USP.